Other Briefings
Investing in Sriperumbudur: Tamil Nadu’s High-Value Manufacturing Corridor
Sriperumbudur in Tamil Nadu is emerging as one of India’s most strategic high-value corridors, propelled by electronics production and a strong global OEM presence, including Foxconn. The region offers foreign investors a scalable and de-risked platform for advanced manufacturing investment in India through 2026.
What Counts as an “Industry” Under Indian Law? Supreme Court to Decide on March 17-18
India’s Supreme Court will revisit the definition of “industry” under the Industrial Disputes Act, 1947, a ruling that could directly influence the interpretation and implementation of the Industrial Relations Code, 2020.
New FEMA Guarantees Framework: From Approval-Centric Controls to a Principle-Led Regime
The RBI has replaced the Foreign Exchange Management (Guarantees) Regulations, 2000, with the 2026 Regulations, introducing a principle-based, eligibility-driven framework under FEMA while retaining the underlying statutory prohibition structure.
India’s Orange Economy: Creative Industries Outlook After Budget 2026
As of 2026, India’s orange economy is emerging as a high-growth services opportunity, spanning media, live concerts, AVGC, and creative industries, supported by policy reform.
India’s Antitrust Regulator CCI Fines Intel US$3.01 Million for Abuse of Dominant Position
Antitrust regulator CCI has imposed a US$3.01 million fine on Intel Corporation for an India-specific warranty policy deemed discriminatory and restrictive of parallel imports. The ruling clarifies how dominance is assessed under Indian competition law and highlights key compliance risks global companies.
Deepfake, Content Labeling & Safe Harbor Risks for Global Platforms: India’s 2026 AI Regulation
India’s latest updates to the IT (Intermediary Guidelines and Digital Media Ethics Code) Rules, 2021, tighten artificial intelligence (AI) and deepfake regulation with mandatory labeling and 2-3 hour takedowns, putting safe harbor protection at risk for foreign platforms.
India Fast-Tracks New Drug & Clinical Trial Approvals with 2026 NDCT Amendments
India’s 2026 amendments to the New Drug and Clinical Trials (NDCT) Rules, 2019, materially improve the operating environment for pharmaceutical companies, contract manufacturers, and foreign investors by compressing approval timelines and reducing pre-licensing bottlenecks.
India’s Component Warehousing Safe Harbor: A Competitive Tax Proposition for Global Manufacturers
India’s Budget 2026-27 introduces a 2 percent safe harbor for bonded component warehousing and a five-year tax exemption for non-resident suppliers, offering transfer pricing certainty and strengthening India’s role in global manufacturing supply chains.
